Advertisement
Advertisement
WGS
GeneDx Holdings Corp. Class A Common Stock
77.08
USDSponsored
+7.49
+10.76%
Aug 07, 15:59 UTC -4
Closed
After-Market
76.75
-0.33
-0.43%
WGS Earnings Reports
Positive Surprise Ratio
WGS beat 14 of 20 last estimates.
70%
Next Report
Date of Next Report
Oct 26, 2026
Estimate for Q3 26 (Revenue/ EPS)
$132.06M
/$0.15
Implied change from Q2 26 (Revenue/ EPS)
+15.40%
/+1400.00%
Implied change from Q3 25 (Revenue/ EPS)
+13.12%
/-69.39%
GeneDx Holdings Corp. Class A Common Stock earnings per share and revenue
On Aug 03, 2026, WGS reported earnings of 0.01 USD per share (EPS) for Q2 26, beating the estimate of -0.18 USD, resulting in a 105.28% surprise. Revenue reached 114.44 million, compared to an expected 112.12 million, with a 2.07% difference. The market reacted with a +4.48% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of 0.15 USD, with revenue projected to reach 132.06 million USD, implying an increase of 1400.00% EPS, and increase of 15.40% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Sotera Health Company Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.24
Actual
$0.26
Surprise
+7.62%
Establishment Labs Holdings Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.34
Actual
-$0.39
Surprise
-13.67%
Progyny, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.34
Actual
$0.55
Surprise
+60.96%
Natera, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.47
Surprise
+6.67%
Viatris Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.61
Actual
$0.69
Surprise
+12.58%
Omada Health, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.01
Actual
$0.15
Surprise
+1,020.25%
Nutex Health Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$5.05
Actual
$9.58
Surprise
+89.59%
CryoPort, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.20
Surprise
-1.16%
Shoulder Innovations, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.46
Surprise
+2.85%
Embecta Corp. Common Stock
Report Date
Aug 07, 2026 For Q3 26
Estimate
$0.27
Actual
$0.56
Surprise
+107.18%
FAQ
What were GeneDx Holdings Corp. Class A Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, GeneDx Holdings Corp. Class A Common Stock reported EPS of $0.01, beating estimates by 105.28%, and revenue of $114.44M, 2.07% above expectations.
How did the market react to GeneDx Holdings Corp. Class A Common Stock's Q2 2026 earnings?
The stock price moved up 4.48%, changed from $67.86 before the earnings release to $70.90 the day after.
When is GeneDx Holdings Corp. Class A Common Stock expected to report next?
The next earning report is scheduled for Oct 26, 2026.
What are the forecasts for GeneDx Holdings Corp. Class A Common Stock's next earnings report?
Based on 10
analysts, GeneDx Holdings Corp. Class A Common Stock is expected to report EPS of $0.15 and revenue of $132.06M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement